Beijing Friendship Hospital
首都医科大学附属北京友谊医院
Listed for 26 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at Beijing Friendship Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌12 papers led
- Hepatocellular carcinoma肝细胞癌51 papers led1 open trial led
- Stomach cancer胃癌45 papers led7 open trials led
- Hepatoblastoma肝母细胞瘤1 paper led
- Retinoblastoma视网膜母细胞瘤1 paper led
- Osteosarcoma骨肉瘤2 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
- Neuroblastoma神经母细胞瘤47 papers led
- Ewing sarcoma尤文肉瘤1 paper led
- Multiple myeloma多发性骨髓瘤1 paper led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症52 papers led3 open trials led
- Haemophilia A血友病 A0 papers led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
- IgG4-related diseaseIgG4相关性疾病12 papers led
- Myasthenia gravis重症肌无力1 paper led
- Wilson disease肝豆状核变性(Wilson 病)4 papers led1 open trial led
- Biliary atresia胆道闭锁4 papers led
- Takayasu arteritis大动脉炎2 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
- Pompe disease庞贝病1 paper led
- Behçet disease白塞病1 paper led
- IgA nephropathyIgA 肾病0 papers led
- Gaucher disease戈谢病2 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎12 papers led1 open trial led
- Primary sclerosing cholangitis原发性硬化性胆管炎4 papers led
- Hirschsprung disease先天性巨结肠0 papers led
Not listed for: Nasopharyngeal carcinoma, Chordoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Moyamoya disease, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Duchenne muscular dystrophy, Alport syndrome, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 12 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.
- Open trials led
- 0
- recruiting or about to
13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led12
- Unraveling the tumor microenvironment of esophageal squamous cell carcinoma through single-cell sequencing: A comprehensive review.
- Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes.
- Lysophosphatidic acid promotes ESCC progression by increasing the level of CCL2 secreted by esophageal epithelial cells.
- Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis.
- Endoscopic Submucosal Dissection for Hypervascularized Esophageal Squamous Cell Carcinoma in Decompensated Cirrhosis With Esophageal Varices and Scars.
- Expression and Significance of N-myc downstream regulated gene 2 in the process of Esophageal Squamous Cell Carcinogenesis.
- Clinical characteristics, prognostic factors, and survival trends in esophageal neuroendocrine carcinomas: A population-based study.
- Porphyromonas gingivalis secretion leads to dysplasia of normal esophageal epithelial cells via the Sonic hedgehog pathway.
- Circ_0001821 Affects Proliferation and the Cell Cycle in Esophageal Squamous Cell Carcinoma by Elevating BTRC-Mediated IKBA Ubiquitination.
- Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature.
- Comorbid early esophageal cancer and Gongylonema pulchrum infection: a case report.
- Lysophosphatidic acid mediated PI3K/Akt activation contributed to esophageal squamous cell cancer progression.
All its trials on ClinicalTrials.gov, any status8
- Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)2
Cancer
Hepatocellular carcinoma
肝细胞癌Led 51 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.
17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingHCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07780357
Age 18 years to Not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led51
- Unstable Recompensation: An Intermediate Subtype in Patients With HBV-Related Decompensated Cirrhosis.
- Role of the nucleotide excision repair function of CETN2 in the inhibition of the sensitivity of hepatocellular carcinoma cells to oxaliplatin.
- Predicting Treatment Response to Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients using a Deep Learning-based Approach.
- Novel immune-related prognostic models for patients with hepatocellular carcinoma after curative resection.
- Stage-Specific Transcriptome Landscape of Hepatocellular Carcinoma: Insights From Super and Poor Survivors With Prognostic Signature Identification.
- Monitoring Sorafenib Resistance and Efficacy in Hepatocellular Carcinoma Using [18F]Alfatide II and [18F]Fluorodeoxyglucose Positron Emission Tomography.
- Novel role of general transcript factor IIH subunit 2 (GTF2H2) in the development and sex disparity of hepatocellular carcinoma.
- Deep learning for hepatocellular carcinoma recurrence before and after liver transplantation: a multicenter cohort study.
- Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.
- Preoperative prediction power of radiomics and non-radiomics methods based on MRI for early recurrence in hepatocellular carcinoma: a systemic review and meta-analysis.
- Deep learning-based arterial subtraction images improve the detection of LR-TR algorithm for viable HCC on extracellular agents-enhanced MRI.
- The timing phase affected the inconsistency of APHE subtypes of liver observations in patients at risk for HCC on the multi-hepatic arterial phase imaging.
- The Diagnostic Accuracy Between Radiomics Model and Non-radiomics Model for Preoperative of Microvascular Invasion of Solitary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
- Inter-reader agreement of LI-RADS treatment response algorithm among three readers with different seniorities for hepatocellular carcinoma after locoregional therapy.
- Optimizing LI-RADS: ancillary features screened from LR-3/4 categories can improve the diagnosis of HCC on MRI.
- Preoperative evaluation of microvascular invasion in hepatocellular carcinoma with a radiological feature-based nomogram: a bi-centre study.
- Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.
- Risk of transplant rejection associated with ICIs prior to liver transplantation in HCC: A multicenter retrospective study.
- Changing spectrum and mortality disparities of etiology of liver cirrhosis in Beijing, China.
- Ablative Treatments and Surgery for Early-Stage Hepatocellular Carcinoma: A Network Meta-Analysis.
- MRI-based radiomics model and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma.
- Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
- The clinical management of hepatocellular carcinoma in China: Progress and challenges.
- Comparison of quantitative volumetric analysis and linear measurement for predicting the survival of Barcelona Clinic Liver Cancer 0- and A stage hepatocellular carcinoma after radiofrequency ablation.
- The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.
- Recompensation in treatment-naïve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding.
- Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis.
- Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis.
- Platelet membrane-derived microparticles may be biomarkers in patients with hepatocellular carcinoma and can promote the invasion and metastasis of hepatoma carcinoma cells.
- Histological assessment based on liver biopsy: the value and challenges in NASH drug development.
- Diagnostic performance of imaging features in the HBP of gadoxetate disodium-enhanced MRI for microvascular invasion in hepatocellular carcinoma: a meta-analysis.
- High-throughput circular RNA sequencing reveals the profiles of circular RNA in non-cirrhotic hepatocellular carcinoma.
- Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features.
- CT-based skeletal muscle loss for predicting poor survival in patients with hepatocellular carcinoma experiencing curative hepatectomy plus adjuvant transarterial chemoembolization: a preliminary retrospective study.
- Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease.
- Roles of small extracellular vesicles in the development, diagnosis and possible treatment strategies for hepatocellular carcinoma (Review).
- Clinical evidence of outcomes following liver transplantation in patients with nonalcoholic steatohepatitis: An updated meta-analysis and systematic review.
- Predictive value of hepatic venous pressure gradient and efficacy and significance of early PTVE for gastrointestinal bleeding after TACE for liver cancer.
- Predictors of mid-term survival after liver transplantation in patients with NAFLD cirrhosis.
- Predicting hepatocellular carcinoma early recurrence after ablation based on magnetic resonance imaging radiomics nomogram.
- Downregulation of HULC Induces Ferroptosis in Hepatocellular Carcinoma via Targeting of the miR-3200-5p/ATF4 Axis.
- Baicalin suppresses the progression of Type 2 diabetes-induced liver tumor through regulating METTL3/m6A/HKDC1 axis and downstream p-JAK2/STAT1/clevaged Capase3 pathway.
- Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints.
- Exosome-derived GTF2H2 from Huh7 cells can inhibit endothelial cell viability, migration, tube formation, and permeability.
- Role of tight junction-associated MARVEL protein marvelD3 in migration and epithelial-mesenchymal transition of hepatocellular carcinoma.
- Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation.
- Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis.
- Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.
- Does Training in LI-RADS Version 2018 Improve Readers' Agreement with the Expert Consensus and Inter-reader Agreement in MRI Interpretation?
- Magnetic resonance radiomics signatures for predicting poorly differentiated hepatocellular carcinoma: A SQUIRE-compliant study.
- Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma.
Chinese-language papers (not in the count)5
- [Application and prospects of magnetic resonance imaging techniques in the diagnosis and evaluation of hepatocellular carcinoma].
- [Construction of a stable centromere protein F overexpression cell model of hepatocellular carcinoma using CRISPR activation system].
- [Expression and Clinical Significance of ATP Citrate Lyase in Hepatocellular Carcinoma].
- [Low-level viremia-induced liver fibrosis and hepatocellular carcinoma in chronic hepatitis B].
- [Correlation among age, sex, and liver diseases-related mortality risk in patients with hepatitis B virus-related liver cirrhosis].
All its trials on ClinicalTrials.gov, any status5
- HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
- Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Cancer
Stomach cancer
胃癌Led 45 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.5%.
15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 11
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingDigital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07441850
Age 18 years to 70 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingRetrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset
- Phase
- Not given
- Started
- 2026-05
- Registry
- NCT07747688
Age 18 years to 90 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingImage-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07835087
Age 18 years to 80 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingIparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07315854
Age 18 years to 80 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingAdebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT07353684
Age 18 years to 75 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingFluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)
- Phase
- N/A
- Started
- 2024-02
- Registry
- NCT06788548
Age 18 years to 80 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingValidating a Medical AI Fine-Tuning Platform for Major Diseases
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT07795645
Age 18 years to Not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingPhase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07700979
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06846996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led45
- Comparison on the reflux and nutritional status of different reconstruction methods after laparoscopic proximal gastrectomy: a systematic review and network meta-analysis.
- Clinicopathological characteristics of 30 cases of pyloric gland adenoma: a single center case series.
- Lectin-affinity glycosylation pattern analysis of plasma extracellular vesicles: An all-in-one clinical assessment for gastric cancer diagnosis and treatment.
- Fusobacterium nucleatum drives gastric cancer metastasis via Gbp-CypA-NF-κB-mediated CXCL8 crosstalk between tumor cells and mast cells.
- Helicobacter pylori CagA promotes gastric cancer immune escape by upregulating SQLE.
- Functions and Clinical Applications of Exosomes in Gastric Cancer.
- Generation of surgical reports for lymph node dissection during laparoscopic gastric cancer surgery based on artificial intelligence.
- Efficient Metabolomics Profiling from Plasma Extracellular Vesicles Enables Accurate Diagnosis of Early Gastric Cancer.
- Prognostic implications of the interaction between intratumoral microbiome and immune response in gastric cancer.
- Incidental Finding of a Primary Polypoid Low-Grade B-Cell Gastric Lymphoma Managed with Chemotherapy.
- Development and validation of a nomogram incorporating dietary factors for predicting Helicobacter pylori-negative early gastric cancer risk.
- Clinicopathologic and endoscopic characteristics of ten patients with gastric hamartomatous inverted polyp: a single center case series.
- Chinese national clinical practice guidelines on the prevention, diagnosis, and treatment of early gastric cancer.
- Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: A systematic review with meta-analysis.
- Risk factors and a nomogram for predicting local recurrence in adult patients with early gastric cancer after endoscopic submucosal dissection.
- Investigating biomechanical alterations and emptying patterns after various gastrojejunostomy strategy.
- A nomogram for predicting survival based on hemoglobin A1c and circulating tumor cells in advanced gastric cancer patients receiving immunotherapy.
- Artificial intelligence for automatic surgical phase recognition of laparoscopic gastrectomy in gastric cancer.
- Assessment of risk factors of lymph node metastasis and prognosis of Siewert II/III adenocarcinoma of esophagogastric junction: A retrospective study.
- Helicobacter pylori promotes gastric fibroblast proliferation and migration by expulsing exosomal miR-124-3p.
- LncRNA CASC19 promotes gastric cancer progression through preventing CREB1 protein ubiquitin/proteasome-dependent degradation.
- LncRNA CASC19: a novel oncogene involved in human cancer.
- Efficacy and safety of combination chemotherapy regimens containing taxanes for first-line treatment in advanced gastric cancer.
- Both extracellular vesicles from helicobacter pylori-infected cells and helicobacter pylori outer membrane vesicles are involved in gastric/extragastric diseases.
- TRIM28 suppresses cancer stem-like characteristics in gastric cancer cells through Wnt/β-catenin signaling pathways.
- Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model.
- Predictive performance of radiomics for peritoneal metastasis in patients with gastric cancer: a meta-analysis and radiomics quality assessment.
- Identification and evaluation of novel serum autoantibody biomarkers for early diagnosis of gastric cancer and precancerous lesion.
- Safety and efficacy of augmented-rectangle technique versus delta-shaped anastomosis for treating gastric cancer in total laparoscopic distal gastrectomy.
- Safety and efficacy of laparoscopic proximal gastrectomy with SOFY versus laparoscopic total gastrectomy with Roux-en-Y for treating cT1-2 Siewert II/III adenocarcinoma of the esophagogastric junction: a single-center prospective cohort stu
- Circulating Tumor Cells as Diagnostic Markers of Early Gastric Cancer and Gastric Precancerous Lesions.
- Endoscopic and clinicopathologic features of early gastric signet ring cell carcinoma ≤20 mm: a retrospective observational study.
- Comparison of endoscopic submucosal dissection outcomes between early gastric cardiac and non-cardiac cancers: a retrospective single-center study.
- Autoimmune gastritis with a gastric hamartomatous inverted polyp and two hyperplastic polyps: a case report.
- External validation of the BEST-J score and a new risk prediction model for ESD delayed bleeding in patients with early gastric cancer.
- MiR-1298-5p level downregulation induced by Helicobacter pylori infection inhibits autophagy and promotes gastric cancer development by targeting MAP2K6.
- Deep biopsy via endoscopic submucosal dissection for primary gastric amyloidosis.
- Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression.
- Gastric lesions in patients with autoimmune metaplastic atrophic gastritis: a retrospective study in a single center.
- Short-term outcomes of three rare cases of intramucosal Epstein-Barr virus-associated gastric cancer treated with endoscopic submucosal dissection.
- Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR-Hippo-YAP pathway.
- The Significance of Exosomal RNAs in the Development, Diagnosis, and Treatment of Gastric Cancer.
- IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer.
- Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma.
- Asporin represses gastric cancer apoptosis via activating LEF1-mediated gene transcription independent of β-catenin.
Chinese-language papers (not in the count)3
- [Application research of endoscopic-laparoscopic regional gastric resection combined with sentinel lymph node basin dissection in patients with early gastric cancer].
- [Pathological features of early gastric cancer and its background mucosa after eradication of Helicobacter pylori and their implications for biopsy diagnosis].
- [Analysis of the clinical confusion and controversy of esophagogastric junction tumor from basic anatomy].
All its trials on ClinicalTrials.gov, any status25
- Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset
- Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer
- Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy
- Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
- Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
- Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)
- Validating a Medical AI Fine-Tuning Platform for Major Diseases
- Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers Diagnosis
- Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
- Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis
- Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer
- Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer
- Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer
- Expanded Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer in China
- A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer
- Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection for Early Gastric Cancer
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer
Cancer
Hepatoblastoma
肝母细胞瘤Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Beijing for hepatoblastoma88 hospitals in China for hepatoblastoma
No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Cancer
Retinoblastoma
视网膜母细胞瘤Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Beijing for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
- Incidental detection of Ewing sarcoma in the thoracic spinal cord by 18F-FDG PET/CT in a pediatric patient with cerebral infarction.
- Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study.
Earlier papers (2016–2020)4
- LOXL1-AS1 predicts poor prognosis and promotes cell proliferation, migration, and invasion in osteosarcoma.
- Overexpression of FER1L4 promotes the apoptosis and suppresses epithelial-mesenchymal transition and stemness markers via activating PI3K/AKT signaling pathway in osteosarcoma cells.
- Systematic meta-analysis of genetic variants associated with osteosarcoma susceptibility.
- Meta-analysis of clinical significance of p53 protein expression in patients with osteosarcoma.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Cancer
Neuroblastoma
神经母细胞瘤Led 47 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 4.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led47
- Solitary Humeral Metastasis in the Absence of Detectable Primary Neuroblastoma on Triple-tracer Imaging With 18F-FDG, 123I-MIBG, and 68Ga-DOTATATE.
- False Positive of 123 I-MIBG Caused by Ectopic Thymic Rebound Hyperplasia in a Pediatric Neuroblastoma.
- Unusual Initial Presentation of Epileptic Seizures in a Pediatric Patient With Neuroblastoma Detected by 18 F-FDG PET/CT Imaging.
- 18 F-FDG PET/CT Demonstrates Left Adrenal Neuroblastoma in a Pediatric Patient With Beckwith-Wiedemann Syndrome.
- 68 Ga-DOTATATE Uptake in Pulmonary Lymphangitic Carcinomatosis: A Rare Form of Metastasis in Pediatric Neuroblastoma.
- Comparison of Iodine-123 Metaiodobenzylguanidine scintigraphy with SPECT/CT and Fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide PET/CT in recurrent High-risk neuroblastoma after complete remission.
- 18F-FDG PET/CT volumetric parameter predicts prognosis for neuroblastoma with MYCN gain.
- Application of modified Curie and SIOPEN skeleton scoring systems in 18F-AlF-NOTA-octreotide PET/CT for neuroblastoma.
- The baseline 18F-FDG PET/CT imaging features in pediatric patients with congenital neuroblastoma.
- The prognostic significance of semi-quantitative metabolic parameters and tumoral metabolic activity based on 123I-MIBG SPECT/CT in pretreatment neuroblastoma patients.
- The Role of 18 F-AlF-NOTA-Octreotide PET/CT in the Evaluation of Central Nervous System Metastases in Neuroblastoma : A Preliminary Study.
- Completely Negative 123 I-MIBG SPECT/CT, but Strong Positive 68 Ga-DOTATATE PET/CT of Multiple Metastases in a Neuroblastoma Patient.
- Recurrent Solitary Pleural Metastasis Originating From Neuroblastoma as Demonstrated by 123I-MIBG Scan.
- Pseudoprogression on 68Ga-DOTATATE PET/CT in a Pediatric Patient With Neuroblastoma.
- Positive 18 F-FDG PET/CT and Negative 123 I-MIBG SPECT/CT Imaging in an Unusual Diaphragmatic Metastasis From Ganglioneuroblastoma.
- Incidental Detection of Choroid Plexus Metastasis From Neuroblastoma Demonstrated by 68 Ga-DOTATATE PET/CT.
- False-Positive Uptake of 123 I-MIBG in the Basal Ganglion in a Pediatric Neuroblastoma Patient.
- 68 Ga-DOTATATE PET/CT Demonstrated More Lesions of Leptomeningeal Metastases Compared With 123 I-MIBG SPECT/CT in a Pediatric Neuroblastoma Patient.
- Concurrent Intracranial and Spinal Dural Metastases Demonstrated by 68 Ga-DOTATATE PET/CT With Negative 123 I-MIBG SPECT/CT in a Pediatric Neuroblastoma Patient.
- A False-Negative 123 I-MIBG SPECT/CT With True-Positive 68 Ga-DOTATATE PET/CT in a Patient With Neuroblastoma Following 177 Lu-DOTATATE Therapy.
- Predictive value of multiparametric diagnostic model based on 2-[18F]-fluoro-D-glucose (2-[18F]-FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in differentiating between neuroblastoma and ganglioneurobla
- Radiomics analysis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography for differentiating the histological classification of peripheral neuroblastic tumours.
- A head-to-head prospective comparative analysis of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT/CT in central nervous system metastases of neuroblastoma and ganglioneuroblastoma.
- GD2-targeted theranostics of neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8.
- Radiomics-based prediction of pathological subtypes in peripheral neuroblastic tumors using 123I-MIBG SPECT/CT imaging: an observational study.
- Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas.
- Differentiation of early relapse and late relapse in intermediate- and high-risk neuroblastoma with an 18F-FDG PET/CT-based radiomics nomogram.
- Prognostic Value of Metabolic Parameters and Textural Features in Pretreatment 18F-FDG PET/CT of Primary Lesions for Pediatric Patients with Neuroblastoma.
- 18F-FDG PET/CT-Based Radiomics Nomogram for Prediction of Bone Marrow Involvement in Pediatric Neuroblastoma: A Two-Center Study.
- Whole-tumoral metabolic heterogeneity in 18F-FDG PET/CT is a novel prognostic marker for neuroblastoma.
- Jaundice as a Rare Presentation of Neuroblastoma in a Pediatric Patient.
- Coexistence of Langerhans Cell Histiocytosis and Ganglioneuroblastoma Revealed by 18 F-FDG PET/CT in a Pediatric Patient.
- Solitary Dural Metastasis From Neuroblastoma Detected by 123 I-MIBG SPECT/CT.
- Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pediatric opsoclonus myoclonus ataxia syndrome presenting with neuroblastoma.
- Predicting event-free survival after induction of remission in high-risk pediatric neuroblastoma: combining 123I-MIBG SPECT-CT radiomics and clinical factors.
- An Optimal Radiomics Nomogram Based on 18F-FDG PET/CT for Identifying Event-Free Survival in Pediatric Neuroblastoma.
- Axial Skeleton Radiomics of 18F-FDG PET/CT: Impact on Event-Free Survival Prediction in High-Risk Pediatric Neuroblastoma.
- Diagnostic Value of 18F-FDG PET/CT-Based Radiomics Nomogram in Bone Marrow Involvement of Pediatric Neuroblastoma.
- Leptomeningeal Metastasis From Neuroblastoma Revealed by 123 I-MIBG SPECT/CT.
- Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification.
- Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma.
- Clinical parameters combined with radiomics features of PET/CT can predict recurrence in patients with high-risk pediatric neuroblastoma.
- The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients.
- MIBG Uptake in Pancreas as a Normal Variant.
- The Diagnostic Value of 18F-FDG PET/CT Bone Marrow Uptake Pattern in Detecting Bone Marrow Involvement in Pediatric Neuroblastoma Patients.
- An 18F-FDG PET/CT radiomics nomogram for differentiation of high-risk and non-high-risk patients of the International Neuroblastoma Risk Group Staging System.
- Diagnostic Value of Seven Different Imaging Modalities for Patients with Neuroblastic Tumors: A Network Meta-Analysis.
Cancer
Ewing sarcoma
尤文肉瘤Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 1 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.06%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma
No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 52 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 13.0%.
11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingProspective Single-Arm Clinical Trial of GO Regimen for HLH.
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Registry
- NCT07339345
Age 14 years to 70 years (registered criteria)
Led by Beijing Friendship HospitalBeijing
- Not yet recruitingEfficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
- Phase
- N/A
- Started
- 2023-08
- Registry
- NCT05988177
Age 18 years to Not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- Not yet recruitingSegmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06131489
Age 18 years to Not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingA Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07208058
Age 16 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led52
- Monocyte/macrophages may exert prominent roles in macrophage activation syndrome.
- Clinical and prognostic significance of whole blood Epstein-Barr virus DNA in patients with primary hemophagocytic lymphohistiocytosis: a retrospective observational study from China.
- CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone).
- Epstein-Barr virus infection and prognosis in haemophagocytic lymphohistiocytosis patients with underlying rheumatic diseases: a single-centre retrospective study.
- The effectiveness of etoposide-containing chemotherapy regimens in the initial treatment of Hemophagocytic Syndrome in pregnancy.
- Epstein-Barr virus infection plays a crucial role in triggering hemophagocytic lymphohistiocytosis in patients with X-linked inhibitor of apoptosis protein deficiency.
- Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding.
- Exploring the Complexities of Liver Transplantation for Secondary Hemophagocytic Lymphohistiocytosis-Associated Acute Liver Failure.
- Characteristics of epilepsy associated with hemophagocytic lymphohistiocytosis.
- The effectiveness of the doxorubicin-etoposide-methylprednisolone regimen for adult HLH secondary to rheumatic disease.
- A convenient and practical index for predicting the induction response in adult patients with hemophagocytic lymphohistiocytosis: ferritin/platelet ratio.
- Haemophagocytic lymphohistiocytosis caused by GATA2 deficiency: a report on three patients.
- Transplantation in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: yes or no?
- Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells.
- Enhancing diagnostic precision in EBV-related HLH: a multifaceted approach using 18F-FDG PET/CT and nomogram integration.
- Etiological stratification and prognostic assessment of haemophagocytic lymphohistiocytosis by machine learning on onco-mNGS data and clinical data.
- The efficacy and safety of chidamide in combination with etoposide and glucocorticoids for the treatment of hemophagocytic lymphohistiocytosis in adult patients: an open-label, single-center study.
- Acute kidney injury in critical care: complications of hemophagocytic lymphohistiocytosis.
- Beta 2-microglobulin is an independent risk marker of acute kidney injury in adult patients with hemophagocytic lymphohistiocytosis.
- Prognostic scoring system for pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis based on baseline characteristics: A multicenter retrospective study.
- Ocular Phenotypes in Patients With Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis in a Single Center Over 7 Years.
- Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.
- Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives.
- Case Report: HAVCR2 mutation-associated Hemophagocytic lymphohistiocytosis.
- Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation.
- Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study.
- The diagnostic importance of multiple cytokines in adult hemophagocytic lymphohistiocytosis.
- L-DEP regimen is effective as an initial therapy for adult EBV-HLH.
- Epstein-Barr virus central nervous system involvement in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
- Clinical characteristics and treatment of NK/T-cell lymphoma-associated HLH.
- Serum ferritin is a good indicator for predicting the efficacy of adult HLH induction therapy.
- Macrophage activation syndrome in adults: Characteristics, outcomes, and therapeutic effectiveness of etoposide-based regimen.
- The Outcome of Induction Therapy for EBV-Related Hemophagocytic Lymphohistiocytosis: A Model for Risk Stratification.
- Outcomes of allogeneic hematopoietic stem cell transplantation for primary hemophagocytic lymphohistiocytosis in adults.
- A Study on Early Death Prognosis Model in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.
- Development and Validation of 18F-FDG PET/CT-Based Multivariable Clinical Prediction Models for the Identification of Malignancy-Associated Hemophagocytic Lymphohistiocytosis.
- Prognosis predicting value of semiquantitative parameters of visceral adipose tissue and subcutaneous adipose tissue of 18F-FDG PET/CT in newly diagnosed secondary hemophagocytic lymphohistiocytosis.
- Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
- Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis.
- Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis.
- Successful resolution of hemophagocytic lymphohistiocytosis during the chemotherapy course of acute myelocytic leukemia with ruxolitinib.
- Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis.
- Multiple-Organ Involvement in Familial Hemophagocytic Lymphohistiocytosis Type 2 Shown on FDG PET/CT.
- Clinical and laboratory signs of haemophagocytic lymphohistiocytosis associated with pandemic influenza A (H1N1) infection in patients needing extracorporeal membrane oxygenation: A retrospective observational study.
- Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment.
- Epstein-Barr virus infection is an important cause of hemophagocytic lymphohistiocytosis during chemotherapy for lymphoma.
- Hemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in an immunocompetent patient.
- Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection.
- Non-EBV infection-associated hemophagocytic lymphohistiocytosis: a distinct subgroup where pathogen-directed therapy is essential and favorable outcomes are expected.
- The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis.
- Epidemiological investigation of hemophagocytic lymphohistiocytosis in China.
- Clinical and laboratory characteristics of hemophagocytic lymphohistiocytosis induced by Leishmania infantum infection.
Chinese-language papers (not in the count)8
- [Clinical Characteristics Analysis of EBV-associated Hemophagocytic Lymphohistiocytosis Patients with Acute Kidney Injury].
- [Clinical and genetic mutation characteristics of patients with primary hemophagocytic lymphohistiocytosis and their impact on prognosis].
- [Characteristic and prognosis of patients with non-EBV infection-associated hemophagocytic lymphohistiocytosis].
- [Evaluation of CD107a and perforin expression detection in the diagnosis of primary hemophagocytic lymphohistiocytosis].
- [New era of accurate diagnosis of hemophagocytic lymphohistiocytosis].
- [Interpretation of Chinese expert consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with lymphoma (2022)].
- [Exhaustion of CD8+T Lymphocytes Plays a Critical Role in the Pathogenesis of Secondary Hemophagocytic Lymphohistiocytosis].
- [Clinical study on the effect of etoposide-containing induction regimen for adult-onset Still's disease associated hemophagocytic syndrome].
All its trials on ClinicalTrials.gov, any status29
- Prospective Single-Arm Clinical Trial of GO Regimen for HLH.
- Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
- Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
- A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT
- Response Prediction in EBV-HLH Using Metabonomics Analysis
- L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
- Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH
- L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH
- Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients
- Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH
- Zanubrutinib for HLH
- Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCT
- Rituximab Monotherapy for EBV-HLH and CAEBV
- PD-1 Antibody Improve Mixed Chimerism
- Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
- DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH
- PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
- Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.
- Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis
- DEP-Ru Regimen as a Salvage Therapy for HLH
- Etoposide in the First-line Treatment of Adult EBV-HLH
- L-DEP as an Initial Treatment for EBV-HLH
- Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology
- L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
- Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
- Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome
- A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis(HLH)
More papers found outside PubMed (not counted)8
- Anakinra for hemophagocytic lymphohistiocytosis: A real-world, multicenter retrospective study on efficacy, safety, and response durability
- Clinical and genetic features of primary hemophagocytic lymphohistiocytosis: A single-center analysis
- CXCL-9 and IL-18: Potential Biomarkers for Efficacy Evaluation in Refractory Hemophagocytic Lymphohistiocytosis Treated with RED (Ruxolitinib, Emapalumab and Dexamethasone)
- Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study
- Zanubrutinib As Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis in Adults: A Single Center, Prospective Study
- Caebv Disease Originates from Infected Hematopoietic Stem Cells
- Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society
- P9.40: Liver Transplantation for Secondary Hemophagocytic Lymphohistiocytosis Associated Acute Liver Failure: A Case Report
Blood disorders
Haemophilia A
血友病 ALed no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingLongitudinal Cohort of Thrombosis and Hemostasis Diseases
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06727669
Age not stated (registered criteria)
Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingLongitudinal Cohort of Thrombosis and Hemostasis Diseases
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06727669
Age not stated (registered criteria)
Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgG4-related disease
IgG4相关性疾病Led 12 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 4.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07061938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led12
- Does adjunctive endoscopic biliary drainage improve outcomes beyond glucocorticoids alone in IgG4-related pancreatobiliary disease?
- Correlations between IgG4-related disease and allergic reactions: implications for future therapeutic strategies.
- Animal models of IgG4-related disease.
- Risk factors for relapse of IgG4-related disease: a systematic review and meta‑analysis.
- Diagnostic value of a novel salivary gland ultrasound scoring system in IgG4-related sialadenitis.
- Systematic analysis for clinical characteristics and outcomes of IgG4-related disease patients during the COVID-19 pandemic.
- Performance of the 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease in a Large Chinese Cohort.
- Three cases of IgG4-RD complicated by splenic artery aneurysm: a complication of IgG4-RD?
- Association Between Immunoglobulin G4-Related Ophthalmic Disease and Nonlymphoid Malignancy Case Series and Comprehensive Review of the Literature.
- Clinical characteristics of IgG4-related respiratory disease patients: a large Chinese cohort study.
- Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients.
- The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
All its trials on ClinicalTrials.gov, any status2
More papers found outside PubMed (not counted)1
Other diseases
Myasthenia gravis
重症肌无力Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis
No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Other diseases
Wilson disease
肝豆状核变性(Wilson 病)Led 4 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 2.0%.
3 hospitals in Beijing for Wilson disease28 hospitals in China for Wilson disease
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingChina Registry for Genetic / Metabolic Liver Diseases
- Phase
- Not given
- Started
- 2015-06
- Registry
- NCT03131427
Age not stated (registered criteria)
Led by Beijing Friendship Hospital; 1 listed hospital as study siteBeijing
- RecruitingTrientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07465718
Age 8 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Dysfunction of ATP7B Splicing Variant Caused by Enhanced Interaction With COMMD1 in Wilson Disease.
- Hepatic progenitor cells reprogrammed from mouse fibroblasts repopulate hepatocytes in Wilson's disease mice.
- Laboratory and clinical evaluation of a microarray for the detection of ATP7B mutations in Wilson disease in China.
- Identification of potential modifier genes in Chinese patients with Wilson disease.
Chinese-language papers (not in the count)3
All its trials on ClinicalTrials.gov, any status2
Other diseases
Biliary atresia
胆道闭锁Led 4 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 1.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Beijing for biliary atresia28 hospitals in China for biliary atresia
No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led4
- Ocular Involvement in Post-Transplantation Lymphoproliferative Disorder: A Rare Case with Rituximab Hypersensitivity.
- Short limb in biliary tract reconstruction: A retrospective study of living donor liver transplantation in children with biliary atresia.
- Association of Gut Microbiota and Metabolites With Disease Progression in Children With Biliary Atresia.
- Post-transplant Lymphoproliferative Disorder in Recipient's Reconstructed Middle Hepatic Vein After Pediatric Living Donor Liver Transplant: A Case Report.
Chinese-language papers (not in the count)1
More papers found outside PubMed (not counted)1
Other diseases
Takayasu arteritis
大动脉炎Led 2 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status6
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Other diseases
Pompe disease
庞贝病Led 1 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 3.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Beijing for Pompe disease30 hospitals in China for Pompe disease
No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- Phase
- Phase 3
- Started
- 2023-11
- Registry
- NCT06145893
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led1
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgA nephropathy
IgA 肾病Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Gaucher disease
戈谢病Led 2 of the 30 English-language PubMed papers on Gaucher disease with an author in mainland China, 2021–2025: 6.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Beijing for Gaucher disease41 hospitals in China for Gaucher disease
No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 12 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 4.0%.
16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPBC Long-term Outcomes Study
- Phase
- Not given
- Started
- 2025-05
- Registry
- NCT07149675
Age not stated (registered criteria)
Led by Beijing Friendship HospitalBeijing
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingSeladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- Phase
- Phase 3
- Started
- 2023-09
- Registry
- NCT06051617
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led12
- Autoimmune liver diseases in the Asia Pacific region: proceedings of the autoimmune liver disease course at APASL 2025.
- Double-negative T cells in combination with ursodeoxycholic acid ameliorates immune-mediated cholangitis in mice.
- GLOBE Score and UK-PBC Risk Score Predict Long-Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate.
- Clinicopathologic Features of a Rare and Underrecognized Variant of Early-stage Primary Biliary Cholangitis With Ductopenia.
- Primary Biliary Cholangitis Associated with Ulcerative Colitis: Case Series and Literature Review.
- Obliteration of portal venules contributes to portal hypertension in biliary cirrhosis.
- Concomitant gallstone disease was not associated with long-term outcomes in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
- Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis.
- APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.
- Reciprocal alterations in circulating and hepatic gamma-delta T cells in patients with primary biliary cholangitis.
- Rare liver diseases are not rare in China.
- Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
Chinese-language papers (not in the count)3
- [Research progress on early-stage primary biliary cholangitis accompanied by portal hypertension].
- [Clinical features and long-term prognosis of primary biliary cholangitis in patients with past hepatitis B virus infection].
- [Recommendations of APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis].
Earlier papers (2016–2020)10
- Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis.
- Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
- Alteration of liver-infiltrated and peripheral blood double-negative T-cells in primary biliary cholangitis.
- Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
- A brief review on prognostic models of primary biliary cholangitis.
- [Risk factors and therapeutic strategies for primary biliary cholangitis patients with poor prognosis].
- [Research advances in primary biliary cholangitis].
- Optimal Adaptive Statistical Iterative Reconstruction Percentage in Dual-energy Monochromatic CT Portal Venography.
- Quantitative fibrosis parameters highly predict esophageal-gastro varices in primary biliary cirrhosis.
- Dual Energy CT (DECT) Monochromatic Imaging: Added Value of Adaptive Statistical Iterative Reconstructions (ASIR) in Portal Venography.
All its trials on ClinicalTrials.gov, any status8
- PBC Long-term Outcomes Study
- Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
- Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis
- Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 4 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 4.0%.
- Open trials led
- 0
- recruiting or about to
10 hospitals in Beijing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07387549
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Autoimmune liver diseases in the Asia Pacific region: proceedings of the autoimmune liver disease course at APASL 2025.
- MRI findings of confluent hepatic fibrosis caused by different etiologies.
- Prevalence and clinical profiles of primary sclerosing cholangitis in China: Data from electronic medical records and systematic literature retrieval.
- Rare liver diseases are not rare in China.
Chinese-language papers (not in the count)2
Other diseases
Hirschsprung disease
先天性巨结肠Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Beijing for Hirschsprung disease82 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other linked evidence
Getting in touch
Name card to show staff or a driver
首都医科大学附属北京友谊医院
Beijing Friendship Hospital
北京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Capital Medical University Affiliated Beijing Friendship Hospital; Beijing Friendship Hospital Affiliated to Capital Medical University; Beijing Friendship Hospital of Capital Medical University; Beijing friendship hospital; Beijing Friendship Hospital Cancer Center; Beijing Friendship Hospita; Library of Beijing Friendship Hospital; Beijing Friendship Hospital of the Capital Medical University